Prophylactic drains are commonly inserted during both major and minor hepatectomy procedures.
Patients with HIV and those with a history of intravenous drug use may have significantly higher rates of hepatic steatosis.
Increased blood glucose levels, even within the nondiabetic range, are associated with increased risk for nonalcoholic fatty liver disease.
Epclusa is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A inhibitor.
From 1990 to 2017, there were increases in the number of primary liver cancer cases among those diagnosed at ages 30 to 59 and ≥60 years.
The challenges associated with managing cirrhosis in patients undergoing non-hepatic surgery specifically are discussed.
In patients with a known diagnosis of cirrhosis, hepatic exacerbations may increase the risk for hospitalization for epilepsy and status epilepticus.
The source of fats in an individual’s diet may alter the risk of developing hepatocellular carcinoma.
From 2000 to 2016, there were large increases in alcohol-induced death rates across age and racial/ethnic subgroups.
A heterogeneous pattern on ultrasound examination of the liver may help identify children with cystic fibrosis at increased risk for developing advanced CF liver disease.
With the use of age-adjusted thresholds for noninvasive markers of liver steatosis and fibrosis, patients with type 2 diabetes may be referred more efficiently to specialists.
Noninvasive scoring systems have modest predictive ability to identify the future development of severe liver disease in patients in the general population.
For patients with unresectable hepatocellular carcinoma, the combination of atezolizumab and bevacizumab is associated with longer time to deterioration of patient-reported quality of life.
In China, researchers investigate the sustained virologic response and safety profile of coblopasvir plus sofosbuvir taken once daily for 12 weeks among patients with HCV genotypes 1, 2, 3, or 6 infections, including individuals with compensated cirrhosis.
The Public Health England Hepatitis C Virus Resistance Group recommended testing resistance for treatment of the hepatitis C virus by using a genotypic testing method of either the Sanger sequencing or next-generation sequencing methods.
Intolerance to treatment with direct acting antiviral treatment was found to be associated with older age and advanced liver disease in patients with hepatocellular carcinoma.
The median change in HCC tumor size between responders and nonresponders was statistically significant.
As emergency departments (EDs) are critical settings for hepatitis C care in the United States, investigators evaluated trends and characteristics of hepatitis C-associated ED visits from 2006 to 2014.
In this study, deterioration in specific PROs required a drop of at least 10 points from baseline.
In a small patient cohort, researchers found that heart transplantation from donors who were hepatitis C virus-positive to recipients without the virus were successful.